- Home
- KRMD vs CHRS Comparison
KRMD vs CHRS Comparison
Compare KRMD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- CHRS
- Stock Information
- Founded
- KRMD 1980
- CHRS 2010
- Country
- KRMD United States
- CHRS United States
- Employees
- KRMD N/A
- CHRS N/A
- Industry
- KRMD Medical/Dental Instruments
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRMD Health Care
- CHRS Health Care
- Exchange
- KRMD Nasdaq
- CHRS Nasdaq
- Market Cap
- KRMD 134.3M
- CHRS 84.2M
- IPO Year
- KRMD N/A
- CHRS 2014
- Fundamental
- Price
- KRMD $3.63
- CHRS $0.90
- Analyst Decision
- KRMD Strong Buy
- CHRS Buy
- Analyst Count
- KRMD 4
- CHRS 3
- Target Price
- KRMD $4.63
- CHRS $4.68
- AVG Volume (30 Days)
- KRMD 450.7K
- CHRS 1.2M
- Earning Date
- KRMD 08-06-2025
- CHRS 08-07-2025
- Dividend Yield
- KRMD N/A
- CHRS N/A
- EPS Growth
- KRMD N/A
- CHRS N/A
- EPS
- KRMD N/A
- CHRS N/A
- Revenue
- KRMD $35,083,740.00
- CHRS $272,251,000.00
- Revenue This Year
- KRMD $18.16
- CHRS N/A
- Revenue Next Year
- KRMD $14.60
- CHRS $106.56
- P/E Ratio
- KRMD N/A
- CHRS N/A
- Revenue Growth
- KRMD 19.65
- CHRS 19.87
- 52 Week Low
- KRMD $1.86
- CHRS $0.66
- 52 Week High
- KRMD $5.05
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- KRMD 66.92
- CHRS 59.04
- Support Level
- KRMD $3.54
- CHRS $0.73
- Resistance Level
- KRMD $3.83
- CHRS $0.82
- Average True Range (ATR)
- KRMD 0.20
- CHRS 0.04
- MACD
- KRMD 0.01
- CHRS 0.02
- Stochastic Oscillator
- KRMD 84.80
- CHRS 88.02
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.